Literature DB >> 31675163

Diagnostic Value of Gd-EOB-DTPA-Enhanced MRI for the Expression of Ki67 and Microvascular Density in Hepatocellular Carcinoma.

Yidi Chen1, Xiali Qin1, Liling Long1, Ling Zhang1, Zhongkui Huang1, Zijian Jiang1, Chenhui Li2.   

Abstract

CONTRACT GRANT SPONSOR: National Natural Science Foundation of China; Contract grant number: 81260214.
BACKGROUND: Recent studies have highlighted the diagnostic value of Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI in small hepatocellular carcinoma (HCC). Ki67 and CD34 are histologic markers that reflect the proliferation of tumor cells and the microvascular density (MVD).
PURPOSE: To explore the diagnostic value of Gd-EOB-DTPA-enhanced MRI for Ki67 expression and MVD in HCC. STUDY TYPE: Retrospective.
SUBJECTS: In all, 180 patients with HCC. FIELD STRENGTH/SEQUENCE: 3.0T, Gd-EOB-DTPA-enhanced T1 WI volumetric interpolated breath-hold examination (VIBE) axial fat suppression plain, and enhanced scanning. ASSESSMENT: The T1 relaxation time (T1 rt) and signal intensity (SI) of the lesion were measured. The Ki67 expressions and MVD were evaluated by immunohistochemistry. STATISTICAL TEST: Receiver operating characteristic (ROC) curves were used to analyze the diagnostic efficacy of T1 rt for high Ki67 expression (≥50%) and high MVD (≥100).
RESULTS: The T1 rt-20min, rrT1 rt-20min, and SI-hepatobiliary phase (SI-HBP) were strongly correlated with Ki67, the r values were 0.846, -0.765, and -0.760 (P < 0.05), respectively. There were moderate correlations with CD34, with r values -0.444, 0.336, and -0.463 (P < 0.05), respectively. The T1 rt-Pre, T1 rt-20min, SI-Pre, and SI-HBP were significantly different both between the high and low ki67 expression groups (P < 0.05) and between the high MVD and low MVD groups (P < 0.05). In the two groups the T1 rt-20min and SI-HBP was 800.06 ± 128.91 vs. 530.06 ± 139.29 (P < 0.05) and 122.29 ± 39.39 vs. 173.49 ± 46.15 (P < 0.05); T1 rt-20min was found to have high diagnostic efficiency for high ki67 expression (area under the curve [AUC], 0.937; P < 0.05) T1 rt-20min had moderate diagnostic value for high MVD (AUC, 0.716; P < 0.05). DATA
CONCLUSION: The T1 rt and SI of Gd-EOB-DTPA-enhanced MRI were correlated with Ki67 expression and MVD. T1 rt-20min has a high diagnostic value for high ki67 expression and high MVD in HCC tissues. LEVEL OF EVIDENCE: 3 Technical Efficacy Stage: 2 J. Magn. Reson. Imaging 2020;51:1755-1763.
© 2019 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  CD34 antigen; Ki-67 antigen; hepatocellular carcinoma; magnetic resonance imaging

Mesh:

Substances:

Year:  2019        PMID: 31675163     DOI: 10.1002/jmri.26974

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

1.  Noninvasively predict the micro-vascular invasion and histopathological grade of hepatocellular carcinoma with CT-derived radiomics.

Authors:  Xu Tong; Jing Li
Journal:  Eur J Radiol Open       Date:  2022-05-16

2.  Nomogram Based on CT Radiomics Features Combined With Clinical Factors to Predict Ki-67 Expression in Hepatocellular Carcinoma.

Authors:  Cuiyun Wu; Junfa Chen; Yuqian Fan; Ming Zhao; Xiaodong He; Yuguo Wei; Weidong Ge; Yang Liu
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

3.  Impact of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging on the prognosis of hepatocellular carcinoma after surgery.

Authors:  Shingo Shimada; Toshiya Kamiyama; Tatsuhiko Kakisaka; Tatsuya Orimo; Akihisa Nagatsu; Yoh Asahi; Yuzuru Sakamoto; Daisuke Abo; Hirofumi Kamachi; Akinobu Taketomi
Journal:  JGH Open       Date:  2020-10-30

4.  Evaluation of the Therapeutic Effect of Adjuvant Transcatheter Arterial Chemoembolization Based on Ki67 After Hepatocellular Carcinoma Surgery.

Authors:  Yu-Fei Zhao; Xiu Xiong; Kai Chen; Wei Tang; Xu Yang; Zheng-Rong Shi
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.